SCHEMBL12936767

SCHEMBL12936767

COC[C@H](N)C(=O)OC(C)(C)C

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOS1 P29475 2/20 0.36
NOS3 P29474 1/20 0.36
NOS2 P35228 1/20 0.36
DGAT1 O75907 1/20 0.34
LTA4H P09960 1/20 0.34
SLC7A5 Q01650 1/20 0.33
LMNA P02545 2/20 0.32
PMP22 Q01453 1/20 0.32
NLRP3 Q96P20 1/20 0.32
CA12 O43570 1/20 0.32
CA14 Q9ULX7 1/20 0.32
KMT2A Q03164 2/20 0.31
CA1 P00915 1/20 0.31
CA2 P00918 1/20 0.31
CA7 P43166 1/20 0.31
GRIN2D O15399 1/20 0.30
GRIN3B O60391 1/20 0.30
GRIN1 Q05586 1/20 0.30
GRIN2A Q12879 1/20 0.30
GRIN2B Q13224 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30227945 1.00 NOS1 (0.36) NOS1NOS3NOS2DGAT1LTA4H
SCHEMBL2735019 1.00 NOS1 (0.36) NOS1NOS3NOS2DGAT1LTA4H
Hydrochloric Acid SCHEMBL6435071 1.00 NOS1 (0.36) NOS1NOS3NOS2DGAT1LTA4H
Hydrochloric Acid SCHEMBL522782 0.86 MAPK1 (0.40) NOS1NOS3NOS2LTA4HSLC7A5
Hydrochloric Acid SCHEMBL522784 0.86 MAPK1 (0.40) NOS1NOS3NOS2LTA4HSLC7A5
Hydrochloric Acid SCHEMBL318950 0.86 MAPK1 (0.40) NOS1NOS3NOS2LTA4HSLC7A5
SCHEMBL8660482 0.85 DGAT1 (0.34) NOS1NOS3NOS2DGAT1SLC7A5
SCHEMBL17643740 0.84 NOS1 (0.38) NOS1NOS3NOS2DGAT1LTA4H
SCHEMBL17630153 0.84 NOS1 (0.38) NOS1NOS3NOS2DGAT1LTA4H
SCHEMBL522812 0.83 MAPK1 (0.41) NOS1NOS3NOS2DGAT1LTA4H

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150266920-A1 MACROCYCLIC KETOAMIDE IMMUNOPROTEASOME INHIBITORS HOFFMANN-LA ROCHE INC. 2015-09-24 US disclosed
EP-2906582-A1 MACROCYCLIC KETOAMIDE IMMUNOPROTEASOME INHIBITORS F. Hoffmann-La Roche AG (CH) 2015-08-19 EP disclosed
US-9085587-B2 Inhibitors of hepatitis C virus PRESIDIO PHARMACEUTICALS, INC. (US) 2015-07-21 US disclosed
WO-2014056954-A1 MACROCYCLIC KETOAMIDE IMMUNOPROTEASOME INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2014-04-17 WO disclosed
US-20120251497-A1 INHIBITORS OF HEPATITIS C VIRUS PRESIDIO PHARMACEUTICALS, INC. 2012-10-04 US disclosed
US-20120251497-A1 INHIBITORS OF HEPATITIS C VIRUS PRESIDIO PHARMACEUTICALS, INC. 2012-10-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150266920-A1 MACROCYCLIC KETOAMIDE IMMUNOPROTEASOME INHIBITORS PSMB7, PSMC2, PSMB8 NOS1 4031/4885NOS3 3593/4885NOS2 3985/4885
US-20120251497-A1 INHIBITORS OF HEPATITIS C VIRUS HAVCR2, LIPC, HCCS NOS1 3234/4885NOS3 2563/4885NOS2 3689/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.